Protamine enhances uptake of cationic liposomes in angiogenic microvessels of solid tumours

Angiogenesis

Volumn 7, Issue 2, 2004, Pages 133-141

  Eichhorn, M E ^a   Strieth, S ^a   Krasnici, S ^a   Sauer, B ^b   Teifel, M ^b   Michaelis, U ^b   Naujoks, K ^b   Dellian, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Munich Biotech AG   (Germany)

Author keywords

cationic liposomes; drug delivery; tumour; vascular targeting

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYLGLYCERO 3 PHOSPHOETHANOLAMINE N (LISSAMINE RHODAMINE B SULFONYL); DIOLEOYLPHOSPHATIDYLCHOLINE; FLUORESCENT DYE; FUCOIDIN; LIPOSOME; PROTAMINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AMELANOTIC MELANOMA; ANALYTIC METHOD; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; CANCER GROWTH; CONTROLLED STUDY; HAMSTER; IMAGE ANALYSIS; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; SKINFOLD; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION;

ANIMALS; BLOOD CELLS; CAPILLARIES; CATIONS; CRICETINAE; DRUG DELIVERY SYSTEMS; LIPOSOMES; MALE; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES; PROTAMINES;

ANIMALIA; CRICETINAE;

EID: 8644270436     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-004-1428-2     Document Type: Article

References (34)

1. Denekamp J. Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-96.
2. Eichhorn ME, Strieth S, Dellian M. Anti-vascular tumor therapy: Recent advances, pitfalls and clinical perspectives. Drug Resist Updat 2004; 7: 125-38.
3. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505-15.
4. Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol 2001; 28: 93-105.
5. Bloemendal HJ, Logtenberg T, Voest EE. New strategies in antivascular cancer therapy. Eur J Clin Invest 1999; 29: 802-9.
6. Olson TA, Mohanraj D, Roy S, Ramakrishnan S. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 1997; 73: 865-70.
7. Thurston G, McLean JW, Rizen M et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101: 1401-13.
8. Krasnici S, Werner A, Eichhorn ME et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105: 561-7.
9. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002; 62: 6831-6.
10. Augustin HG, Braun K, Telemenakis I et al. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 1995; 147: 339-51.
11. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: Analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 1994; 16: 901-6.
12. Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest 2001; 108: 349-55.
13. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002; 62: 6132-40.
14. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1479-84.
15. Kirkpatrick AP, Kaiser TA, Shepherd RD, Rinker KD. Biochemical mediated glycocalyx modulation in human umbilical vein endothelial cells (HUVEC). Summer Bioengineering Conference, June 25-29, 2003.
16. Dass CR. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int J Pharm 2003; 267: 1-12.
17. Kunstfeld R, Wickenhauser G, Michaelis U et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003; 120: 476-82.
18. Strieth S, Eichhorn ME, Sauer B et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110: 117-24.
19. Schmitt-Sody M, Strieth S, Krasnici S et al. Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9: 2335-41.
20. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 2001; 12: 861-70.
21. Sakurai F, Nishioka T, Saito H et al. Interaction between DNA-cationic liposome complexes and erythrocytes is an important factor in systemic gene transfer via the intravenous route in mice: The role of the neutral helper lipid. Gene Ther 2001; 8: 677-86.
22. Sakurai F, Nishioka T, Yamashita F et al. Effects of erythrocytes and serum proteins on lung accumulation of lipoplexes containing cholesterol or DOPE as a helper lipid in the single-pass rat lung perfusion system. Eur J Pharm Biopharm 2001; 52: 165-72.
23. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR). Guidelines for the welfare of animals in experimental neoplasia, second edition. Br J Cancer 1998; 77: 1-10.
24. Asaishi K, Endrich B, Götz A, Messmer K. Quantitative analysis of microvascular structure and function in the amelanotic melanoma A-Mel-3. Cancer Res 1981; 41: 1898-904.
25. Butterworth J, Lin YA, Prielipp RC et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002; 74: 1589-95.
26. 1Butterworth J, Lin YA, Prielipp R et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002; 94: 514-22.
27. Stace TM, Damiano ER. An electrochemical model of the transport of charged molecules through the capillary glycocalyx. Biophys J 2001; 80: 1670-90.
28. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000; 440: 653-66.
29. Samoszuk MK, Su MY, Najafi A, Nalcioglu O. Selective thrombosis of tumor blood vessels in mammary adenocarcinoma implants in rats. Am J Pathol 2001; 159: 245-51.
30. Su MY, Samoszuk MK, Wang J, Nalcioglu O. Assessment of protamine-induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI. NMR Biomed 2002; 15: 106-13.
31. Halloran MM, Carley WW, Polverini PJ et al. Ley/H: An endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol 2000; 164: 4868-77.
32. Pevni D, Gurevich J, Frolkis I et al. Protamine induces vasorelaxation of human internal thoracic artery by endothelial NO-synthase pathway. Ann Thorac Surg 2000; 70: 2050-53.
33. Oguchi T, Doursout MF, Kashimoto S et al. Role of heparin and nitric oxide in the cardiac and regional hemodynamic properties of protamine in conscious chronically instrumented dogs. Anesthesiology 2001; 94: 1016-25.
34. Bessa X, Elizalde JI, Mitjans F et al. Leukocyte recruitment in colon cancer: Role of cell adhesion molecules, nitric oxide, and transforming growth factor betal. Gastroenterology 2002; 122: 1122-32.